The MiningNewsWire Podcast

Customer relationship management (“CRM”) is a process in which a business or organization uses data analysis to better understand massive amounts of information to determine the best strategies for interacting with current and potential customers. Evolving from rudimentary surveys in the 1970s used by a handful of companies, CRM has become the biggest software market in the world used by 91% of companies that have more than 11 employees. The market is dynamic and constantly evolving in order to maximize return on investment for companies around the world, with companies such as Infobird Co. Ltd (NASDAQ: IFBD) (Profile) growing rapidly as a name brand in China. Majors such as Alibaba Group Holding Limited (NYSE: BABA) are also part of the market getting in front of emerging trends, as are Zendesk Inc. (NYSE: ZEN), Twilio Inc. (NYSE: TWLO) and Salesforce.com Inc. (NYSE: CRM) by providing the critical software and know-how for companies to improve customer relationships, quickly engage new customers and drive higher sales.

Customer relationship management (“CRM”) is a process in which a business or organization uses data analysis to better understand massive amounts of information to determine the best strategies for interacting with current and potential customers. Evolving from rudimentary surveys in the 1970s used by a handful of companies, CRM has become the biggest software market in the world used by 91% of companies that have more than 11 employees. The market is dynamic and constantly evolving in order to maximize return on investment for companies around the world, with companies such as Infobird Co. Ltd (NASDAQ: IFBD) (Profile) growing rapidly as a name brand in China. Majors such as Alibaba Group Holding Limited (NYSE: BABA) are also part of the market getting in front of emerging trends, as are Zendesk Inc. (NYSE: ZEN), Twilio Inc. (NYSE: TWLO) and Salesforce.com Inc. (NYSE: CRM) by providing the critical software and know-how for companies to improve customer relationships, quickly engage new customers and drive higher sales.

An old investing proverb states “the trend if your friend.” Tested and proven through time, the proverb rarely does an investor wrong. To that point, two emerging trends that should be commanding attention are plant-based foods and food delivery. Both were disrupted during the COVID-19 pandemic but in slightly different ways as consumers became more in tune with their bodies while having to cope with shuttered restaurants amid global lockdowns and social-distancing mandates. With the coronavirus slowly slipping into the rear mirror, these markets should continue their upward treks undergirded by consumers adopting healthier, more convenient lifestyles. At the intersection of plant-based foods and food delivery is PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (Profile), a company on a mission to not just be a brand but also a lifestyle, partner to all brands, and the digital face of the entire plant-based community. Others looking to capitalize on the trend away from animal-based foods include Beyond Meat Inc. (NASDAQ: BYND), Tattooed Chef Inc. (NASDAQ: TTCF), Amazon.com Inc. (NASDAQ: AMZN) and Oatly Group AB (NASDAQ: OTLY).

An old investing proverb states “the trend if your friend.” Tested and proven through time, the proverb rarely does an investor wrong. To that point, two emerging trends that should be commanding attention are plant-based foods and food delivery. Both were disrupted during the COVID-19 pandemic but in slightly different ways as consumers became more in tune with their bodies while having to cope with shuttered restaurants amid global lockdowns and social-distancing mandates. With the coronavirus slowly slipping into the rear mirror, these markets should continue their upward treks undergirded by consumers adopting healthier, more convenient lifestyles. At the intersection of plant-based foods and food delivery is PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (Profile), a company on a mission to not just be a brand but also a lifestyle, partner to all brands, and the digital face of the entire plant-based community. Others looking to capitalize on the trend away from animal-based foods include Beyond Meat Inc. (NASDAQ: BYND), Tattooed Chef Inc. (NASDAQ: TTCF), Amazon.com Inc. (NASDAQ: AMZN) and Oatly Group AB (NASDAQ: OTLY).

The concept of “big data” has been around for decades but only took on its current form in the 21st century with computers running 24/7/365 processing mounds of user data to better understand and predict trends. However, consumers have grown tired of their harvested data exploitation, and winds of change are blowing in new modalities that cater to security and privacy. Nothing is more representative of the ongoing shift than Apple’s recent operating system changes that feature one of the world’s few welcomed pop-ups: one that asks if it’s okay to track your activity. Welcome to the age of “small and wide” data. Companies are already looking to next-generation technology to meet this new demand, including that of Streamlytics (Profile), which doesn’t use cookies or tracking in its human-led data. The mix of consumer and regulatory blowback has all the majors, including Palantir Technologies Inc. Class A (NYSE: PLTR), Snowflake Inc. Class A (NYSE: SNOW), Oracle Corporation (NYSE: ORCL), Salesforce.com Inc (NYSE: CRM) and Microsoft Corporation (NASDAQ: MSFT) dedicated to advanced functionality to meet or surpass obligations for privacy, governance and compliance associated with collecting and using personal information.

The concept of “big data” has been around for decades but only took on its current form in the 21st century with computers running 24/7/365 processing mounds of user data to better understand and predict trends. However, consumers have grown tired of their harvested data exploitation, and winds of change are blowing in new modalities that cater to security and privacy. Nothing is more representative of the ongoing shift than Apple’s recent operating system changes that feature one of the world’s few welcomed pop-ups: one that asks if it’s okay to track your activity. Welcome to the age of “small and wide” data. Companies are already looking to next-generation technology to meet this new demand, including that of Streamlytics (Profile), which doesn’t use cookies or tracking in its human-led data. The mix of consumer and regulatory blowback has all the majors, including Palantir Technologies Inc. Class A (NYSE: PLTR), Snowflake Inc. Class A (NYSE: SNOW), Oracle Corporation (NYSE: ORCL), Salesforce.com Inc (NYSE: CRM) and Microsoft Corporation (NASDAQ: MSFT) dedicated to advanced functionality to meet or surpass obligations for privacy, governance and compliance associated with collecting and using personal information.

In 2020, Canada became the largest exporter of dried cannabis flower in the world. Today, Canada is looking over its shoulder at a formidable competitor in Colombia, which recently instigated some legislative changes that position the country to become the global cannabis leader. Colombia was already recognized for its robust infrastructure, distribution and exports of certain cannabis products such as medicinal oils and extracts, but the country had a gaping hole in exports by keeping dried cannabis flower strictly verboten. That hole was filled on July 23, 2021, when Colombian President Ivan Duque signed a legislative decree ending the prohibition on the export of dried cannabis flower — a significant global market and a potential windfall for Flora Growth Corp. (NASDAQ: FLGC) (Profile) and its expansive global operations. The broader industry should also benefit from this latest development since most majors, including Canopy Growth Corporation (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON) and Sundial Growers Inc. (NASDAQ: SNDL), support the mainstream worldwide evolution of legal cannabis.

In 2020, Canada became the largest exporter of dried cannabis flower in the world. Today, Canada is looking over its shoulder at a formidable competitor in Colombia, which recently instigated some legislative changes that position the country to become the global cannabis leader. Colombia was already recognized for its robust infrastructure, distribution and exports of certain cannabis products such as medicinal oils and extracts, but the country had a gaping hole in exports by keeping dried cannabis flower strictly verboten. That hole was filled on July 23, 2021, when Colombian President Ivan Duque signed a legislative decree ending the prohibition on the export of dried cannabis flower — a significant global market and a potential windfall for Flora Growth Corp. (NASDAQ: FLGC) (Profile) and its expansive global operations. The broader industry should also benefit from this latest development since most majors, including Canopy Growth Corporation (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON) and Sundial Growers Inc. (NASDAQ: SNDL), support the mainstream worldwide evolution of legal cannabis.

One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (“CDC”), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don’t even know they have it. The urgency of finding effective treatments for this life-threatening disease can’t be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (“CDC”), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don’t even know they have it. The urgency of finding effective treatments for this life-threatening disease can’t be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing therapies for hard-to-treat diseases. In November 2013, Gazyva, a drug used in combination with chlorambucil for patients with chronic lymphocytic leukemia, made history as the first breakthrough therapy to receive FDA marketing approval. Since then, hundreds of drugs have earned the designation, and several have reached commercialization. An area that remains underrepresented on the FDA breakthrough therapy list that could make waves in the coming years is that of the emerging market of psychedelics, where companies such as Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is striving to provide relief for patients with chronic pain by developing evidence-based innovation in areas where today’s approved drugs and therapies are lacking. Tryp is part of a select group of companies that are advancing or have already advanced psychedelic treatments into Phase 2 of the FDA clinical trial process, a small collection of impressive companies that includes COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), ATAI Life Sciences N.V. (NASDAQ: ATAI) and Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF).

The $150-billion global advertising industry is looking for answers during a shakeup that has cable television charting a course emblematic of the Golden Age of Radio a century ago. Owing to the confluence of cord cutters, DVRs allowing people to skip commercials and an off-year for elections among other things, local TV ad revenue has been sinking in 2021. Now more than ever, brands are forced to keenly monitor marketing trends and adjust strategies that increasingly point toward digital solutions to reach consumers. Working with content creators and influencers, those people (and things) on social media with a large or specific group of followers that can be swayed into purchases by compelling messaging, appears to be particularly effective. By now, most people are aware of marketing via a personality, such as Kim Kardashian who can influence her followers to try a particular product. While that still has its place, the market is far more evolved and sophisticated today, with companies such as Clubhouse Media Group Inc. (OTC: CMGR) (Profile) aggregating an impressive collection of influencers and content creators with hundreds of millions of followers and combining that community with technology as a platform for collaboration and creation. That type of dynamic is a win-win for advertisers and the world’s most popular social media apps and sites, including Facebook Inc. (NASDAQ: FB), Pinterest Inc. Class A (NYSE: PINS), Snap Inc. Class A (NYSE: SNAP) and Twitter Inc. (NYSE: TWTR).

The $150-billion global advertising industry is looking for answers during a shakeup that has cable television charting a course emblematic of the Golden Age of Radio a century ago. Owing to the confluence of cord cutters, DVRs allowing people to skip commercials and an off-year for elections among other things, local TV ad revenue has been sinking in 2021. Now more than ever, brands are forced to keenly monitor marketing trends and adjust strategies that increasingly point toward digital solutions to reach consumers. Working with content creators and influencers, those people (and things) on social media with a large or specific group of followers that can be swayed into purchases by compelling messaging, appears to be particularly effective. By now, most people are aware of marketing via a personality, such as Kim Kardashian who can influence her followers to try a particular product. While that still has its place, the market is far more evolved and sophisticated today, with companies such as Clubhouse Media Group Inc. (OTC: CMGR) (Profile) aggregating an impressive collection of influencers and content creators with hundreds of millions of followers and combining that community with technology as a platform for collaboration and creation. That type of dynamic is a win-win for advertisers and the world’s most popular social media apps and sites, including Facebook Inc. (NASDAQ: FB), Pinterest Inc. Class A (NYSE: PINS), Snap Inc. Class A (NYSE: SNAP) and Twitter Inc. (NYSE: TWTR).

In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing therapies for hard-to-treat diseases. In November 2013, Gazyva, a drug used in combination with chlorambucil for patients with chronic lymphocytic leukemia, made history as the first breakthrough therapy to receive FDA marketing approval. Since then, hundreds of drugs have earned the designation, and several have reached commercialization. An area that remains underrepresented on the FDA breakthrough therapy list that could make waves in the coming years is that of the emerging market of psychedelics, where companies such as Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is striving to provide relief for patients with chronic pain by developing evidence-based innovation in areas where today’s approved drugs and therapies are lacking. Tryp is part of a select group of companies that are advancing or have already advanced psychedelic treatments into Phase 2 of the FDA clinical trial process, a small collection of impressive companies that includes COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), ATAI Life Sciences N.V. (NASDAQ: ATAI) and Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF).

Cryptocurrency mining, where banks of specialized computers rush to solve complex algorithms and build data blocks of transaction activity on the blockchain to earn cryptocurrency, is energy intensive, to say the least. From the outset, China kept a stranglehold on the market owing to abundant and cheap energy, including in the coal plant hubs of inner Mongolia and Xinjiang, resulting in more than half of the world’s mining activity occurring in the country. However, Beijing is facing pressure to control carbon emissions, and it is pointing its finger directly at cryptomining for its failure to meet targets. To that end, Chinese regulators have taken unprecedented action in shutting down crypto miners, shining a spotlight on cleaner energy solutions, like those offered by ISW Holdings Inc. (OTC: ISWH) (Profile), which just got a head start in a race for power in the United States. The Chinese shutdown also means that all those coins that would have been mined by Chinese firms are up for grabs, which is good news for ISWH and crypto miners such as Marathon Digital Holdings Inc. (NASDAQ: MARA), CleanSpark Inc. (NASDAQ: CLSK), Riot Blockchain Inc (NASDAQ: RIOT) and Bitfarms Ltd. (NASDAQ: BITF).

Cryptocurrency mining, where banks of specialized computers rush to solve complex algorithms and build data blocks of transaction activity on the blockchain to earn cryptocurrency, is energy intensive, to say the least. From the outset, China kept a stranglehold on the market owing to abundant and cheap energy, including in the coal plant hubs of inner Mongolia and Xinjiang, resulting in more than half of the world’s mining activity occurring in the country. However, Beijing is facing pressure to control carbon emissions, and it is pointing its finger directly at cryptomining for its failure to meet targets. To that end, Chinese regulators have taken unprecedented action in shutting down crypto miners, shining a spotlight on cleaner energy solutions, like those offered by ISW Holdings Inc. (OTC: ISWH) (Profile), which just got a head start in a race for power in the United States. The Chinese shutdown also means that all those coins that would have been mined by Chinese firms are up for grabs, which is good news for ISWH and crypto miners such as Marathon Digital Holdings Inc. (NASDAQ: MARA), CleanSpark Inc. (NASDAQ: CLSK), Riot Blockchain Inc (NASDAQ: RIOT) and Bitfarms Ltd. (NASDAQ: BITF).

Global Extended Reality Market size expected to grow from 33 billion USD in 2021 to over 125 billion USD in 2026, at CAGR of 30%

US online sports betting market size expected to grow at 50% CAGR to reach 15 billion by 2025

Online gambling market size expected to grow at 11.5% CAGR to reach 127 billion USD by 2027

XR Casino, Inc. (“XR Casino” or “The Company”), the first-ever cross-technology, multiplayer, blockchain technology-based online gambling platform for Extended Reality (“XR”) technologies such as Augmented Reality (“AR”), Mixed Reality (“MR”) and Virtual Reality (“VR”), today announces its MVP release date.

To read the original press release, visit: https://nnw.fm/10QVT

Rritual Superfoods Inc. ("Rritual" or the "Company") (CSE: RSF) (FSE: 0RW) (OTC: RRSFF), a fast-growing functional superfood company that creates natural wellness products which support a holistic approach to a healthy lifestyle, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Rritual's recent announcement that its premium brand of functional superfoods will launch in CVS stores across the USA.

To hear the audio production, visit: https://www.nnw.fm/bFP7j

To read the original press release, visit: https://www.nnw.fm/V9sYE

Rritual Superfoods Inc. ("Rritual" or the "Company") (CSE: RSF) (FSE: 0RW) (OTC: RRSFF), a fast-growing functional superfood company that creates natural wellness products which support a holistic approach to a healthy lifestyle, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Rritual's recent announcement that its premium brand of functional superfoods will launch in CVS stores across the USA.

To hear the audio production, visit: https://www.nnw.fm/bFP7j

To read the original press release, visit: https://www.nnw.fm/V9sYE

In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain momentum at that time, and while countless companies saturated the market as would-be growers, distributors, etc., GW was taking a more difficult route of drug development with much greater upside if successful. The strategy paid off as the company received FDA approval for the first-ever cannabis-based drug in June 2018. There are some notable similarities between the evolution of the legal cannabis market a decade ago and the current status of psychedelics, longtime illicit drugs that are now being evaluated for their therapeutic potential by a handful of upstart companies. San Diego-based Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) stands out, not only for its still-small valuation but also because it has a successful management team that, much like GW, is charting its own course in the space. Major investors have not been shy about speculating that biotech is going to produce some psychedelic-derived blockbusters, as evidenced by the attention given to COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (“MindMed”) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and newly public ATAI Life Sciences N.V. (NASDAQ: ATAI), any one of which could do for psychedelics what GW Pharmaceuticals (NASDAQ: GWPH) did for cannabis before being acquired in February by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for $7.2 billion.